World Health Organization Issues Alert Over Severe Lack of Weight-Loss Jabs

Under a tenth of individuals who could benefit from weight-loss injections such as Wegovy have access to them, warns the WHO as it releases its first recommendations on the drugs.

With in excess of 1,000,000,000 individuals worldwide now obese, it is calling for increased and just availability to this class of drugs.

Per estimates, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.

"Our new guidelines affirms that obesity is a lifelong illness that can be treated with holistic and ongoing support," said the agency's head Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and logistical bottlenecks are major barriers to widespread availability to the injections that can assist patients in reducing substantial body mass, explains the body.

Weight-Loss Drug Supply Crisis

Even in the current best projected outlook, the supply of these medications could only cover approximately 100 million people – under 10% of eligible patients, as stated by the WHO.

The recommendation calls on governments and firms to widen availability, through approaches like licensing agreements.

Exclusive production rights on the active ingredient – the main component of a leading brand – is set to lapse in multiple countries in 2026.

How Obesity Drugs Operate

The injections replicate a biological compound to delay gastric emptying, suppress the appetite and boost the sense of being full so users eat less.

People usually see weight reduction within a few weeks of starting on the regular doses.

Evidence suggests patients may regain a significant portion after a year of stopping the drug, as their usual appetite resume.

To be carrying excess weight elevates your chance for developing medical conditions, like type 2 diabetes, heart disease, stroke, and certain malignancies.

Obesity impacts individuals in countries worldwide and was associated with millions of fatalities worldwide in 2024, as per the WHO.